Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
Gene | FBXW7 |
Variant | W486* |
Impact List | nonsense |
Protein Effect | loss of function - predicted |
Gene Variant Descriptions | FBXW7 W486* results in a premature truncation of the Fbxw7 protein at amino acid 486 of 707 (Uniprot.org). W486* results in increased tumorigenesis in mouse models (PMID: 24838835), and therefore, is predicted to lead to a loss of Fbxw7 protein function. |
Associated Drug Resistance | |
Category Variants Paths |
FBXW7 mutant FBXW7 inact mut FBXW7 W486* |
Transcript | NM_033632.3 |
gDNA | chr4:g.152326193C>T |
cDNA | c.1457G>A |
Protein | p.W486* |
Source Database | RefSeq |
Genome Build | GRCh38/hg38 |
Transcript | gDNA | cDNA | Protein | Source Database | Genome Build |
---|---|---|---|---|---|
NM_033632 | chr4:g.152326193C>T | c.1457G>A | p.W486* | RefSeq | GRCh38/hg38 |
XM_047415897.1 | chr4:g.152326193C>T | c.1457G>A | p.W486* | RefSeq | GRCh38/hg38 |
NM_018315.4 | chr4:g.152324342C>T | c.1457G>A | p.W486* | RefSeq | GRCh38/hg38 |
XM_017008362 | chr4:g.152326193C>T | c.1457G>A | p.W486* | RefSeq | GRCh38/hg38 |
NM_033632.3 | chr4:g.152326193C>T | c.1457G>A | p.W486* | RefSeq | GRCh38/hg38 |
NM_033632.3 | chr4:g.152326193C>T | c.1457G>A | p.W486* | RefSeq | GRCh38/hg38 |
XM_011532083 | chr4:g.152326193C>T | c.1457G>A | p.W486* | RefSeq | GRCh38/hg38 |
NM_018315 | chr4:g.152324342C>T | c.1457G>A | p.W486* | RefSeq | GRCh38/hg38 |
XM_024454123.1 | chr4:g.152326193C>T | c.1457G>A | p.W486* | RefSeq | GRCh38/hg38 |
XM_011532085.2 | chr4:g.152326193C>T | c.1457G>A | p.W486* | RefSeq | GRCh38/hg38 |
NM_018315.5 | chr4:g.152324342C>T | c.1457G>A | p.W486* | RefSeq | GRCh38/hg38 |
XM_011532085.3 | chr4:g.152326193C>T | c.1457G>A | p.W486* | RefSeq | GRCh38/hg38 |
XM_011532085 | chr4:g.152326193C>T | c.1457G>A | p.W486* | RefSeq | GRCh38/hg38 |
XM_047415900.1 | chr4:g.152326193C>T | c.1457G>A | p.W486* | RefSeq | GRCh38/hg38 |
XM_011532084.3 | chr4:g.152326193C>T | c.1457G>A | p.W486* | RefSeq | GRCh38/hg38 |
NM_001349798.2 | chr4:g.152326193C>T | c.1457G>A | p.W486* | RefSeq | GRCh38/hg38 |
XM_047415899.1 | chr4:g.152326193C>T | c.1457G>A | p.W486* | RefSeq | GRCh38/hg38 |
XM_024454122.1 | chr4:g.152326193C>T | c.1457G>A | p.W486* | RefSeq | GRCh38/hg38 |
XM_024454121.1 | chr4:g.152326193C>T | c.1457G>A | p.W486* | RefSeq | GRCh38/hg38 |
XM_047415898.1 | chr4:g.152326193C>T | c.1457G>A | p.W486* | RefSeq | GRCh38/hg38 |
XM_047415901.1 | chr4:g.152326193C>T | c.1457G>A | p.W486* | RefSeq | GRCh38/hg38 |
NM_001349798.1 | chr4:g.152326193C>T | c.1457G>A | p.W486* | RefSeq | GRCh38/hg38 |
XM_024454123.2 | chr4:g.152326193C>T | c.1457G>A | p.W486* | RefSeq | GRCh38/hg38 |
XM_011532084 | chr4:g.152326193C>T | c.1457G>A | p.W486* | RefSeq | GRCh38/hg38 |
XM_011532084.2 | chr4:g.152326193C>T | c.1457G>A | p.W486* | RefSeq | GRCh38/hg38 |
XM_024454124.1 | chr4:g.152326193C>T | c.1457G>A | p.W486* | RefSeq | GRCh38/hg38 |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
FBXW7 inact mut | Advanced Solid Tumor | resistant | Docetaxel | Preclinical | Actionable | In a preclinical study, human cancer cell lines harboring FBXW7 inactivating mutations were resistant to docetaxel in culture (PMID: 23274910). | 23274910 |
FBXW7 inact mut | hematologic cancer | sensitive | Belinostat | Preclinical | Actionable | In a preclinical study, Beleodaq (belinostat) inhibited human hematologic cancer cell lines harboring FBXW7 inactivating mutations in culture (PMID: 23274910). | 23274910 |
FBXW7 inact mut | Advanced Solid Tumor | sensitive | Belinostat | Preclinical | Actionable | In a preclinical study, Beleodaq (belinostat) inhibited human cancer cell lines harboring FBXW7 inactivating mutations in culture (PMID: 23274910). | 23274910 |
FBXW7 inact mut | Advanced Solid Tumor | sensitive | Entinostat | Preclinical | Actionable | In a preclinical study, entinostat (MS-275) inhibited cancer cells from advanced solid tumors and hematological cells harboring FBXW7 inactivating mutations in culture (PMID: 23274910). | 23274910 |
FBXW7 inact mut | hematologic cancer | sensitive | REC-2282 | Preclinical | Actionable | In a preclinical study, REC-2282 (AR-42) inhibited human hematologic cancer cell lines harboring FBXW7 inactivating mutations in culture (PMID: 23274910). | 23274910 |
FBXW7 inact mut | breast cancer | sensitive | Sirolimus | Preclinical - Cell line xenograft | Actionable | In a preclinical study, breast cancer cells harboring a FBXW7 mutation demonstrated sensitivity to Rapamune (sirolimus) in culture and in cell line xenograft models (PMID: 18787170). | 18787170 |
FBXW7 inact mut | Advanced Solid Tumor | sensitive | REC-2282 | Preclinical | Actionable | In a preclinical study, REC-2282 (AR-42) inhibited human cancer cell lines harboring FBXW7 inactivating mutations in culture (PMID: 23274910). | 23274910 |
FBXW7 inact mut | hematologic cancer | sensitive | Entinostat | Preclinical | Actionable | In a preclinical study, entinostat (MS-275) inhibited cancer cells from advanced solid tumors and hematological cells harboring FBXW7 inactivating mutations in culture (PMID: 23274910). | 23274910 |
FBXW7 mutant | Her2-receptor negative breast cancer | predicted - sensitive | LY3039478 | Case Reports/Case Series | Actionable | In a Phase I trial, LY3039478 treatment resulted in partial response lasted 9.5 months in a patient with hormone receptor-positive, Erbb2 (Her2)-negative breast cancer harboring FBXW7 mutation (PMID: 30060061; NCT01695005). | 30060061 |